Skip to main content

SCEMBLIX WORKS DIFFERENTLY THAN ATP-COMPETITIVE TKIs1

SCEMBLIX is the first and only inhibitor that binds to the ABL myristoyl pocket.1 The myristoyl pocket is a distinct site of the kinase domain, normally occupied by the myristoylated N-terminal of ABL1 in people who do not have CML.2

In studies conducted in vitro or in animal models of CML, SCEMBLIX showed activity against wild-type BCR::ABL1 and several mutant forms of the kinase, including the T315I mutation.1

IMPORTANT SAFETY INFORMATION 

Myelosuppression

  • Thrombocytopenia, neutropenia, and anemia, including grade 3/4 reactions, have occurred in patients receiving SCEMBLIX

  • Perform complete blood counts every 2 weeks for the first 3 months of treatment and monthly thereafter or as clinically indicated. Monitor patients for signs and symptoms of myelosuppression...

INDICATIONS

SCEMBLIX is indicated for the treatment of adult patients with:

  • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)

  • Ph+ CML in CP with the T315I mutation...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATIONS
References: 1. Scemblix. Prescribing information. Novartis Pharmaceuticals Corp. 2. Hughes TP, Mauro MJ, Cortes JE, et al. N Engl J Med. 2019;381(24):2315-2326. 3. Redaelli S, Piazza R, Rostagno R, et al. J Clin Oncol. 2009;27(3):469-471. 4. Schoepfer J, Jahnke W, Berellini G, et al. J Med Chem. 2018;61(18):8120-8135.